Recursion Publishes Annual Environmental, Social and Governance Report
26 3월 2024 - 9:00PM
Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading
the space by decoding biology to industrialize drug discovery,
today announced the release of its third annual Environmental,
Social and Governance (ESG) Report. The report highlights the
company’s approach, progress and goals in several important areas
such as its commitment to patients, social and community impact,
people and culture, environmental sustainability, and governance.
“Our vision of using AI and technology to create a better, more
efficient process of discovering many new medicines is inherently a
vision of sustainability. Efficiency – in our context – drives a
more sustainable healthcare system,” said Chris Gibson, Ph.D.,
Co-Founder and CEO at Recursion. “Now in our third year of
reporting on our ESG goals and progress, we’re not only pushing the
boundaries of what is possible with TechBio to create a new
paradigm in drug discovery, but also making strides to drive
positive impacts for all of our stakeholders.”
Recursion has been widely recognized for its commitment to
excellence in environmental, social and governance stewardship,
including ranking 16 out of over 900 companies (approximately the
top 2%) in the pharmaceutical category by Morningstar
Sustainalytics as of January 2024. This ranking places Recursion in
Sustainalytics’ 2024 Top-Rated ESG Companies List. Recursion also
received a Prime Rating in 2023 for ESG performance from
Institutional Shareholder Services (ISS). A Prime Rating is awarded
to companies with ESG performance above a sector-specific threshold
and is defined by ISS as "absolute best in class". In February
2024, Recursion received an A Rating for ESG performance by
MSCI.
Recursion’s ESG Report is guided by key ESG frameworks and
standards, notably the Sustainability Accounting Standards Board
(SASB), The Task Force on Climate-Related Financial Disclosures
(TCFD) and the United Nations Sustainable Development Goals
(UN SDGs). You can learn more about Recursion’s approach to ESG and
download a copy of the report at www.Recursion.com/esg.
About Recursion
Recursion is a clinical stage TechBio company leading the space
by decoding biology to industrialize drug discovery. Enabling its
mission is the Recursion OS, a platform built across diverse
technologies that continuously expands one of the world’s largest
proprietary biological, chemical and patient-centric datasets.
Recursion leverages sophisticated machine-learning algorithms to
distill from its dataset a collection of trillions of searchable
relationships across biology and chemistry unconstrained by human
bias. By commanding massive experimental scale — up to millions of
wet lab experiments weekly — and massive computational scale —
owning and operating one of the most powerful supercomputers in the
world, Recursion is uniting technology, biology, chemistry and
patient-centric data to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montreal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on X (formerly Twitter) and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based
upon "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995, including, without
limitation, those regarding its initiatives to reduce greenhouse
gas emissions, improve workforce diversity and accelerate community
impact; and all other statements that are not historical facts.
Forward-looking statements may or may not include identifying words
such as “plan,” “will,” “expect,” “anticipate,” “intend,”
“believe,” “potential,” “continue,” and similar terms. These
statements are subject to known or unknown risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied in such statements, including but not limited
to: challenges inherent in pharmaceutical research and development,
including the timing and results of preclinical and clinical
programs, where the risk of failure is high and failure can occur
at any stage prior to or after regulatory approval due to lack of
sufficient efficacy, safety considerations, or other factors; our
ability to leverage and enhance our drug discovery platform; our
ability to obtain financing for development activities and other
corporate purposes; the success of our collaboration activities;
our ability to obtain regulatory approval of, and ultimately
commercialize, drug candidates; our ability to obtain, maintain,
and enforce intellectual property protections; cyberattacks or
other disruptions to our technology systems; our ability to
attract, motivate, and retain key employees and manage our growth;
inflation and other macroeconomic issues; and other risks and
uncertainties such as those described under the heading “Risk
Factors” in our filings with the U.S. Securities and Exchange
Commission, including our Annual Report on Form 10-K. All
forward-looking statements are based on management’s current
estimates, projections, and assumptions, and Recursion undertakes
no obligation to correct or update any such statements, whether as
a result of new information, future developments, or otherwise,
except to the extent required by applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Recursion Pharmaceuticals (NASDAQ:RXRX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024